INCY
★★★★★ Strong BuymistralIncyte Corporation
Healthcare
Session move
$123.47
Vol 0.65× avg
93/100 quant · tgt $125.17
RS60 +23.2% vs SPY · ADV$ 224.7M
pushed 2026-08-19T10:25 · Pre-market · Pushed snapshot
Since last scan
2026-08-18 → 2026-08-19
Context only — not a buy/sell signal. Built from scan history and cached news/filings.
Snapshot quote
session 2026-08-18 · scan 2026-08-19 · pushed 2026-08-19T10:25 · Pre-market
Show quote fundamentalsHide quote fundamentals
- Last (scan/close)
- $123.47
- Previous close
- $123.50
- Pushed last
- $123.47 · Pre-market
- Session open
- $124.29
- Last session range
- $123.23 – $124.71
- 52-week range
- $81.09 – $132.60
- Session volume
- 1,191,123
- Avg volume (20d)
- 1,836,831
- Market cap
- $25.03B
- PE (TTM)
- 15.71
- Forward PE
- 13.90
- Dividend yield
- 0.00%
- 1y target est.
- $125.17
- Next earnings
- 2026-10-27
Snapshot quote — last daily session bars and scan fundamentals. Not live bid/ask or intraday quotes. Pre/after-hours quotes are thinner and may differ from the regular session.
If you put $1,000 in
1y ago
$1,445
+44%
5y ago
$1,648
+65%
Price path only from cached daily closes (adjusted when available). Not dividends cash, fees, or advice.
Market briefing
Curated digest — not a trade signal. Headlines and links as provided by the producer.
- Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $130
Piper Sandler analyst Allison Bratzel maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $110 to $130.
Benzinga · 2026-08-17
- Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup
Incyte (INCY) shows strong growth momentum with a clean technical setup, combining high earnings growth, positive ratings, and a breakout opportunity.
ChartMill · 2026-08-17
- IHF: Healthcare Dashboard For August
Healthcare sector valuation check: equipment undervalued, providers near baseline, pharma/biotech overvalued. Learn more about IHF ETF here.
SeekingAlpha · 2026-08-17
- Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?
On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte’s INCA033989. The first-in-class monoclonal antibody targets mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms. By utilizing Halozyme’s proprietary ENHANZE drug delivery technology, INCY aims to create a more convenient dosing regimen for patients. […]
Yahoo · 2026-08-14
Reddit mentions
Public Reddit titles via the official API — unofficial, delayed, not a trade signal. Not affiliated with Reddit. Opens Reddit.
No recent Reddit titles matched this ticker.
Price Chart
Daily prices from cache
Loading price history…
AI Analysis
- Bull Thesis — Incyte's 93/100 quant score reflects strong revenue/EPS growth (37.7% YoY), high ROE (30.7%), and consistent FCF margins (20.3%), positioning it well in specialty oncology.
- Risks — Form 4 insider selling (-15 disclosure score) and high 3-month volatility (38.3%) may signal near-term caution despite quant strength.
- Target Upside — Mean analyst target of $125.17 implies 1.4% upside from $123.47, with momentum (29.7% 3M) and earnings surprise (44.6%) supporting valuation.
Score History
17 days of scans. Daily batch adds the next weekday automatically while the API is running.
- DatePriceChgScoreRating
- 2026-08-19$123.47-0.0393.1Strong Buy
- 2026-08-18$123.50+3.3490.1Strong Buy
- 2026-08-17$120.16-0.3691.0Strong Buy
- 2026-08-14$120.52+0.4090.9Strong Buy
- 2026-08-13$120.12-0.9591.0Strong Buy
- 2026-08-12$121.07-0.4890.7Strong Buy
- 2026-08-11$121.55+0.9990.5Strong Buy
- 2026-08-10$120.56+0.0090.8Strong Buy
- 2026-08-09$120.56+0.0093.8Strong Buy
- 2026-08-08$120.56+2.1893.8Strong Buy
- 2026-08-07$118.38-1.4290.9Strong Buy
- 2026-08-06$119.80-0.8091.0Strong Buy
- 2026-08-05$120.60+2.1790.8Strong Buy
- 2026-08-03$118.43-1.0990.9Strong Buy
- 2026-08-01$119.52-0.1390.6Strong Buy
- 2026-07-31$119.65-3.3490.5Strong Buy
- 2026-07-30$122.99—89.6Buy
Quant Breakdown
Short volume (FINRA)
Off-exchange short sale volume ratio vs recent sessions — not a squeeze forecast.
- Short / total
- 71.4%
- vs 20d (z)
- 1.36
- Short vol
- 256,443
- Status
- ok
Squeeze pressure score
full44/100
- Short leg
- 40
- Call leg
- 63
- Activity
- 1.0
- Call vol share
- 76.8%
- PCR (vol)
- 0.30
- Call OI share
- 51.6%
- ATM IV
- 47.0%
FINRA off-exchange short volume (TRF/ADF consolidated). Not short interest as % of float. Squeeze pressure score (0–100) — free composite of off-exchange short volume and (when available) call-side options activity. Not a probability that a squeeze will occur.
Disclosure score
Rule-based News / Insider / Earnings legs from cached SEC filings — context only, not beat/miss or a buy signal.
Disclosure score
-15
- News
- 0
- Insider
- -15
- Earnings
- 0
Signals below are rule hits from cached filings — Risk / Constructive / Attention. Attention is not a bullish call. Linked chips open the SEC original when available.
Disclosure event score — rule-based view of recent SEC filings and earnings calendar. Not a prediction that price will move, and not earnings beat/miss.
Earnings surprise (quant context)
From Yahoo/public fundamentals cached on the last quant scan — not part of the disclosure event score, and not a buy signal. Figure can lag the latest print.
Last reported surprise +0.4%
Filings & events
Recent SEC disclosures and earnings dates — context only, not a trade signal.
- Next earnings
- 2026-10-27yahoo_calendar
- Last earnings
- —
- SEC ↗42026-08-14
FORM 4
- SEC ↗42026-08-07
FORM 4
- SEC ↗42026-08-07
FORM 4
- SEC ↗42026-08-04
FORM 4
- SEC ↗42026-08-04
FORM 4
- SEC ↗10-Q2026-07-28
10-Q
- SEC ↗8-K2026-07-28
8-K
- SEC ↗42026-07-27
FORM 4
- SEC ↗42026-07-27
FORM 4
- SEC ↗42026-07-20
FORM 4
SEC filings as reported; earnings dates may come from Yahoo calendar. Context only — not investment advice and not a prediction that price will move on a filing or event.